The Maison Bourbon Jazz Club is not just another unpredictable lure for tourists who like jazz. The music is authentic and played by some of the best jazz musicians in town. The club says that it is dedicated to "the preservation of jazz."
Registration/Course Enrollment Open
8 a.m.-11 a.m.
IS8. Symptomatic and Functional Recovery: Attainable Goals in Treating Depression?Supported by Wyeth-Ayerst Laboratories
A. What Is Remission; Why Is It Important; and When Does It Occur? Lauren B. Marangell, M.D.
B. Are All Antidepressant Medications Equivalent in Attaining Remission? Michael E. Thase, M.D.
C. Does Combining Medications or Medication Sequences Lead to Remission? Jack M. Gorman, M.D.
D. What Is the Role of Psychotherapy in Attaining Remission? A. John Rush, M.D.
IS9. Critical Decisions in the Lifetime Treatment of Schizophrenia Supported by Eli Lilly and Company
A. First Episode: Establishing Neuroprotection Diana O. Perkins, M.D.
B. Consequences and the Cost of Relapse Gerald A. Maguire, M.D.
C. Neuroplasticity and the Development of Treatment Resistance in Patients With Schizophrenia: Strategies for Prevention Jeffrey A. Lieberman, M.D.
D. Critical Decisions in the Treatment of Adolescent and Pediatric Psychosis Linmarie Sikich, M.D.
E. Cognition Across the Lifetime Richard S.E. Keefe, Ph.D.
IS10. To Work and to Love: Focus on Quality of Life in Mood and Anxiety Disorders Supported by SmithKline Beecham Pharmaceuticals
A. Measures of Quality of Life Jean Endicott, Ph.D.
B. Improving Quality of Life for Patients With Bipolar Disorders Holly A. Schwartz, M.D.
C. Quality of Life in the Anxiety Disorders Mark H. Pollack, M.D.
D. The Impact of Depression and Its Treatment Mark H. Rapaport, M.D.
IS11. Meeting the Challenge of Schizophrenia and Co-Occurring Addictions Supported by Novartis Pharmaceuticals Corporation
A. Schizophrenia and Co-Occurring Disorders: The Scope of the Problem and Impact on Outcomes Lisa B. Dixon, M.D.
B. The Neurobiology of Addiction and Schizophrenia in Relation to the Action of Antipsychotic Drugs Herbert Y. Meltzer, M.D.
C. Pharmacotherapy of Comorbid Substance Use Disorders Alan I. Green, M.D.
D. Integrating Pharmacotherapy and Dual Recovery Therapy Douglas M. Ziedonis, M.D.
E. Best Systems and Practices for Dual Diagnosis Robert E. Drake, M.D.
IS12. Men Over 50: An Endangered Species Supported by Forest Laboratories Inc.
A. Depression and Suicide in Men Over 50 Steven P. Roose, M.D.
B. Vascular Disease and Depression K. Ranga R. Krishnan, M.D.
C. Testosterone Decline in Aging Men: Does Andropause Exist? Stuart N. Seidman, M.D.
D. Age, Sexual Dysfunction, and Depression Raymond C. Rosen, Ph.D.
E. Depression and Dementia in Older Men Gary W. Small, M.D.
S13. Issues in the Long-Term Treatment of Depression Supported by Glaxo Wellcome Inc.
A. Weight Changes During Long-Term Antidepressant Treatment Maurizio Fava, M.D.
B. Antidepressant-Induced Sexual Dysfunction Anita L.H. Clayton, M.D.
C. The Role of Psychotherapy in the Long-Term Treatment of Depression Gabor I. Keitner, M.D.
D. Identification of Depressive Relapse P. Murali Doraiswamy, M.D.
E. Management of Depressive Breakthrough During Long-Term Treatment Jonathan E. Alpert, M.D.
IS14. Alcoholism and Bipolar Disorder: Treatment Options Circa 2000 Supported by Pfizer Inc.
A. New Pharmacotherapies for Alcohol Dependence Barbara J. Mason, Ph.D.
B. Antiepileptic Drugs in Alcohol Withdrawal and Relapse Hugh Myrick, M.D.
C. Suicidality, Impulsivity, and Alcoholism Joseph F. Goldberg, M.D.
D. Bipolar Disorder and Comorbid Alcoholism: Course of Illness and Treatment Implications Mark A Frye, M.D.
E. Antiepileptic Drugs Versus Lithium in the Treatment of Bipolar Illness and Alcohol Use Disorders Mark A. Frye, M.D.
CME Courses 15-20
8 a.m.-4:30 p.m.
APA Resource Center Open
9 a.m.-4 p.m.
CME Courses 21-26
11 a.m.-4:30 p.m.
Publishers’ Bookfair Open
12:30 p.m.-1:30 p.m.
Business Meeting and Forum (voting members only)
1 p.m.-5 p.m.
CME Courses 27-34
1:30 p.m.-4:30 p.m.
IS15. Treating Psychotic Disorders: What Is the State of the Art?Supported by Bristol-Myers Squibb Company
A. Issues in Managing Psychosis in Geriatric Patients Dilip V. Jeste, M.D.
B. Treatment of Depression With Psychosis Robert N. Golden, M.D.
C. Emerging Treatments in Acute Mania and Bipolar Disorders Terence A. Ketter, M.D.
D. Treating the Spectrum of Symptoms in Schizophrenia Jeffrey A. Lieberman, M.D.
E. Treatment of Pediatric Psychosis Judith H.L. Rapoport, M.D.
IS16. Providing Complete Treatment for Patients With Bipolar DisorderSupported by the National Depressive and Manic-Depressive Association and Eli Lilly and Company
A. Manic and Mixed Episodes: The Challenge of Improving Functional Outcome Paul E. Keck Jr., M.D.
B. New Horizons in the Treatment ofBipolar Depression K. N. Roy Chengappa, M.D.
C. Women and Bipolar Disorder Lori L. Altshuler, M.D.
D. Maintenance Treatment for Patients With Bipolar Disorder Joseph F. Goldberg, M.D.
E. The Face of Bipolar Illness: Results of a National Depressive and Manic-Depressive Association Survey Lydia J. Lewis
IS17. MAOIs RevisitedSupported by Somerset Pharmaceuticals Inc.
A. An Update on MAO Inhibitors and Behavior Lynn Wecker, Ph.D.
B. Cellular Antidepressant Mechanism of MAO Inhibitors Pierre Blier, M.D.
C. Clinical Use of MAO Inhibitors Jay D. Amsterdam, M.D.
D. Next Generation of MAO Inhibitors Andrew A. Nierenberg, M.D.
E. Transdermal Selegiline in Depression J. Alexander Bodkin, M.D.
IS18. Advances in the Treatment of Geriatric Depression Supported by Organon Inc.
A. Diagnosis and Treatment of Depression in the Older Patient J. Craig Nelson, M.D.
B. Benefits of Different Classes of Antidepressants for Geriatric Depression Alan F. Schatzberg, M.D.
C. DNA Microarray Technology and the Treatment of Depression Greer M. Murphy, M.D.
D. Pharmacology of Antidepressants Pertinent to Older Patients Bruce G. Pollock, M.D.
IS19. Chemical Restraints: Clinical, Research, and Ethical ImplicationsSupported by Janssen Pharmaceutica
A. Atypical Antipsychotics in the Emergency Setting Glenn W. Currier, M.D.
B. Depot Antipsychotics: An Alternative to Forced Medications Sally A. Berry, M.D.
C. Preventing Psychological Trauma Following Forced Medication Terence M. Keane, Ph.D.
D. Dealing With the New Legal Framework for Chemical Restraints Paul S. Appelbaum, M.D.
E. Historical Legal Trends and Civil Liberties in Forced Medications Renee L. Binder, M.D.
IS20. Atypical Antipsychotic Drugs: How Do They Work?Supported by AstraZeneca Pharmaceuticals
A. What Really Is "Atypical" About Atypical Antipsychotics: Lessons From PET Imaging Studies Shitij Kapur, M.D.
B. Understanding the Action of Antipsychotic Drugs at the Level of Gene Expression Barbara K. Lipska, Ph.D.
C. Intrinsic Circuitry in Cortex: Receptors, Drug Action, and Cognition Patricia S. Goldman-Rakic, Ph.D.
D. Behavioral and Neurochemical Predictors of Antipsychotic Drug Action Charles B. Nemeroff, M.D.
E. Therapeutic Insights From the Clinical Search for Genes Daniel R. Weinberger, M.D.
2:30 p.m.-4 p.m.
L1. Title to Be Announced:Professor Paul E. Mullen, Dr. Michelle Pathe, Rosemary Purcell, AAPL/APA’s Manfred S. Guttmacher Award Lecture
5 p.m.-6:30 p.m.
Opening Session and Presidential Address
7 p.m.-10 p.m.
IS21. Critical Questions in Anxiety DisordersSupported by Wyeth-Ayerst Laboratories
A. Cost Burden of Anxiety Disorders Ronald C. Kessler, Ph.D.
B. Antidepressants and Anxiolytics: Do They All Work in Social Phobia? Jonathan R.T. Davidson, M.D.
C. Should GAD Be Treated Long Term? David V. Sheehan, M.D.
D. Treatment of Comorbid Anxiety and Bipolar Disorders Susan L. McElroy, M.D.
E. Barriers to the Effective Treatment of Anxiety Disorders Mark Olfson, M.D.
IS22. Managing Refractory Anxiety: An International PerspectiveSupported by Solvay Pharmaceuticals Inc.
A. The Functional Impact of Anxiety Disorders: Focus on Social Phobia Murray B. Stein, M.D.
B. Integrating Neuroscience and Psychotherapy: The Study of Human Emotions Donatella Marazziti, M.D.
C. Childhood Anxiety Disorders: NIMH Initiatives Benedetto Vitiello, M.D.
D. Refractory OCD: An International Perspective Eric Hollander, M.D.
E. Anxiety and Suicide Jan A. Fawcett, M.D.
IS23. Treatment-Resistant Depression Across the Life SpanSupported by Pharmacia Inc.
A. The Phenomenology and Course of Treatment-Resistant Depression Patrick J. McGrath, M.D.
B. Pharmacological Treatment Options Maurizio Fava, M.D.
C. Management of Depression in the Medically Ill: Practical Approaches to Treatment Prakash S. Masand, M.D.
D. Juvenile Bipolar Disorder: An Overlooked Condition Janet Wozniak, M.D.
E. Treatment Advances in Geriatric Depression George S. Alexopoulos, M.D.
IS24. Neurobiology, Depression, and the Specificity of Treatment ResponseSupported by Organon Inc.
A. 5HT and Norepinephrine in Depression Pedro L. Delgado, M.D.
B. The Role of Dopamine in Depression and Antidepressant Treatment Alexander H. Glassman, M.D.
C. Brain Structure and Function in Major Depression Harold A. Sackeim, Ph.D.
D. The Biology of Depressive Subtypes and Treatment Response Steven P. Roose, M.D.
IS25. Psychosis of Alzheimer’s Disease: New Knowledge, New Treatment StrategiesSupported by Janssen Pharmaceutica
A. Efficacy of Antipsychotic Agents Ira R. Katz, M.D.
B. Practical Strategies for the Treatment of Psychoses Due to Dementia Jacobo E. Mintzer, M.D.
C. Psychosis of Dementia Lon S. Schneider, M.D.
D. Effects of Other Psychotherapeutic Medications Constantine G. Lyketsos, M.D.
IS26. Moving Toward a More Comprehensive Management of Patients With SchizophreniaSupported by Pfizer Inc.
A. Acute Psychotic Agitation: Exploring New Options Alan J. Mendelowitz, M.D.
B. Beyond the Acute Phase: Issues in Stabilization Peter J. Weiden, M.D.
C. Psychosocial Treatment for Schizophrenia: Strategies for the New Era Nina R. Schooler, Ph.D.
D. Raising the Bar From Symptom Reduction to Disability Reduction Michael F. Green, Ph.D.
E. Improving the Overall Health of Patients With Schizophrenia Daniel E. Casey, M.D.
Session 1. Four Stories of Mother/ Daughter Resilience
1. The Joy Luck Club
Session 2. Psychiatry Goes to the Movies
2. The Conformist American Psychoanalytic Association ▪
New Orleans is tucked along the banks of the meandering Mississippi River. The river enters the Gulf of Mexico about 100 miles downstream from tbe city.
Download citation file:
Please confirm that your email address is correct, so you can successfully receive this alert.
Read this week's Update
Sign Up for Psychiatric News Update newsletter